- Home
- SYRE vs RCUS Comparison
SYRE vs RCUS Comparison
Compare SYRE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- RCUS
- Stock Information
- Founded
- SYRE 2013
- RCUS 2015
- Country
- SYRE United States
- RCUS United States
- Employees
- SYRE N/A
- RCUS N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- SYRE Health Care
- RCUS Health Care
- Exchange
- SYRE Nasdaq
- RCUS Nasdaq
- Market Cap
- SYRE 1.1B
- RCUS 906.4M
- IPO Year
- SYRE 2016
- RCUS 2018
- Fundamental
- Price
- SYRE $17.38
- RCUS $10.53
- Analyst Decision
- SYRE Buy
- RCUS Buy
- Analyst Count
- SYRE 5
- RCUS 8
- Target Price
- SYRE $55.00
- RCUS $20.71
- AVG Volume (30 Days)
- SYRE 490.8K
- RCUS 810.0K
- Earning Date
- SYRE 08-05-2025
- RCUS 08-06-2025
- Dividend Yield
- SYRE N/A
- RCUS N/A
- EPS Growth
- SYRE N/A
- RCUS N/A
- EPS
- SYRE N/A
- RCUS N/A
- Revenue
- SYRE N/A
- RCUS $262,000,000.00
- Revenue This Year
- SYRE N/A
- RCUS N/A
- Revenue Next Year
- SYRE N/A
- RCUS $28.73
- P/E Ratio
- SYRE N/A
- RCUS N/A
- Revenue Growth
- SYRE N/A
- RCUS 6.07
- 52 Week Low
- SYRE $10.91
- RCUS $6.50
- 52 Week High
- SYRE $40.26
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- SYRE 57.01
- RCUS 62.68
- Support Level
- SYRE $15.73
- RCUS $9.92
- Resistance Level
- SYRE $17.42
- RCUS $10.75
- Average True Range (ATR)
- SYRE 0.89
- RCUS 0.56
- MACD
- SYRE 0.07
- RCUS 0.08
- Stochastic Oscillator
- SYRE 86.50
- RCUS 77.83
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.